Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study assessing COVID-HIG for the treatment for severe hospitalized patients as well as protection for at-risk individuals

Trial Profile

A study assessing COVID-HIG for the treatment for severe hospitalized patients as well as protection for at-risk individuals

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COVID-2019 immune globulins (Human) (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Apr 2020 According to an Emergent BioSolutions media release, company and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have agreed to incorporate the company COVID-HIG product candidate into one of NIAID clinical studies for assessment of treatments for COVID-19 once clinical material is available, and the study begins.
    • 26 Mar 2020 New trial record
    • 11 Mar 2020 According to an Emergent BioSolutions media release, this study is expected to begin as early as the third quarter of 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top